Imatinib

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Chronic Myelogenous Leukemia in Chronic Phase

Conditions

Chronic Myelogenous Leukemia in Chronic Phase

Trial Timeline

Nov 1, 2002 → Jun 1, 2007

NCT ID

NCT00237120

About Imatinib

Imatinib is a phase 3 stage product being developed by Novartis for Chronic Myelogenous Leukemia in Chronic Phase. The current trial status is completed. This product is registered under clinical trial identifier NCT00237120. Target conditions include Chronic Myelogenous Leukemia in Chronic Phase.

What happened to similar drugs?

20 of 20 similar drugs in Chronic Myelogenous Leukemia in Chronic Phase were approved

Approved (20) Terminated (3) Active (0)

✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved

✅Telmisartan/Rosuvastatin 40/10mg + Telmisartan 40mgYuhanApproved

✅placebo + aspirin + clopidogrel + aspirin OR prasugrel + aspirinDaiichi SankyoApproved

✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved

✅alefaceptAstellas PharmaApproved

✅AlefaceptAstellas PharmaApproved

✅lysozyme 90 mg + PlaceboEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01392495	Phase 3	Terminated	Jun 1, 2011	Mar 1, 2014	Pulmonary Arterial Hypertension
NCT01137916	Phase 2	Completed	Jun 1, 2010	Dec 1, 2016	Aggressive Fibromatosis
NCT00760981	Phase 1	Completed	Sep 1, 2008	Apr 1, 2012	Graft vs Host Disease
NCT00632255	Pre-clinical	Completed	Jan 1, 2008	May 1, 2009	Chronic Myeloid Leukemia
NCT00426179	Phase 1/2	Completed	Dec 1, 2006	Aug 1, 2007	Seasonal Allergic Rhinitis
NCT00420043	Phase 1	Completed	Sep 1, 2006	Nov 1, 2006	Healthy
NCT00424515	Phase 2	Completed	Jul 1, 2006	Jul 1, 2011	Mucosal Melanoma
NCT00422825	Phase 1	Completed	Jun 1, 2006	Sep 1, 2006	Healthy
NCT00421317	Phase 2	Terminated	Dec 1, 2005	Nov 15, 2009	Melanoma
NCT00150072	Phase 2	Completed	Oct 1, 2004	Apr 1, 2008	Chordoma
NCT00237120	Phase 3	Completed	Nov 1, 2002	Jun 1, 2007	Chronic Myelogenous Leukemia in Chronic Phase
NCT00940563	Phase 2	Completed	Mar 1, 2002	—	Advanced Gastrointestinal Stromal Tumors

Competing Products

20 competing products in Chronic Myelogenous Leukemia in Chronic Phase

See all competitors

Product	Company	Stage	Hype Score
Levofloxacin 500	Dr. Reddy's Laboratories	Pre-clinical	23
mRNA-0184	Moderna	Phase 1	0
Lubiprostone + Lubiprostone + Placebo	Dr. Reddy's Laboratories	Phase 3	37
macitentan 10 mg	BML, Inc.	Phase 3	32
KPL-716 + Placebo	Kiniksa Pharmaceuticals	Phase 2	29
TERN-701	Terns Pharmaceuticals	Phase 1/2	36
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	23
LY3556050 + Placebo	Eli Lilly	Phase 2	35
THB001	Third Harmonic Bio	Phase 1	11
Briquilimab	Jasper Therapeutics	Phase 1/2	26
Briquilimab	Jasper Therapeutics	Phase 1/2	14
Briquilimab	Jasper Therapeutics	Phase 2	29
Empagliflozin + Matching placebo	Eli Lilly	Phase 3	40
LY3461767 + Placebo	Eli Lilly	Phase 1	29
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	44
LY3526318 + Placebo	Eli Lilly	Phase 2	35
Pirtobrutinib	Eli Lilly	Phase 2	42
Ibrutinib + LY3214996	Eli Lilly	Phase 1	21
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	27
LYR-210	Lyra Therapeutics	Phase 2	25